Last reviewed · How we verify

Standard of Care IST

Biogen · Phase 3 active Small molecule

Standard of Care IST is a S1P receptor modulator Small molecule drug developed by Biogen. It is currently in Phase 3 development for Relapsing forms of multiple sclerosis, Active secondary progressive multiple sclerosis.

IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis.

IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis. Used for Relapsing forms of multiple sclerosis, Active secondary progressive multiple sclerosis.

At a glance

Generic nameStandard of Care IST
SponsorBiogen
Drug classS1P receptor modulator
TargetS1P1, S1P3, S1P4, S1P5, S1P6
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

IST works by reducing the number of immune cells that attack the protective covering of nerves in the central nervous system, thereby slowing the progression of multiple sclerosis. This is achieved through the depletion of autoreactive T and B lymphocytes. IST has been shown to reduce the frequency of relapses and slow disease progression in patients with relapsing forms of multiple sclerosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of Care IST

What is Standard of Care IST?

Standard of Care IST is a S1P receptor modulator drug developed by Biogen, indicated for Relapsing forms of multiple sclerosis, Active secondary progressive multiple sclerosis.

How does Standard of Care IST work?

IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis.

What is Standard of Care IST used for?

Standard of Care IST is indicated for Relapsing forms of multiple sclerosis, Active secondary progressive multiple sclerosis.

Who makes Standard of Care IST?

Standard of Care IST is developed by Biogen (see full Biogen pipeline at /company/biogen).

What drug class is Standard of Care IST in?

Standard of Care IST belongs to the S1P receptor modulator class. See all S1P receptor modulator drugs at /class/s1p-receptor-modulator.

What development phase is Standard of Care IST in?

Standard of Care IST is in Phase 3.

What are the side effects of Standard of Care IST?

Common side effects of Standard of Care IST include Increased risk of infections, Headache, Nausea, Diarrhea, Fatigue, Liver enzyme elevations.

What does Standard of Care IST target?

Standard of Care IST targets S1P1, S1P3, S1P4, S1P5, S1P6 and is a S1P receptor modulator.

Related